The PSMD12 antibody is a research tool targeting the PSMD12 protein, a key component of the 26S proteasome. PSMD12 (Proteasome 26S Subunit, Non-ATPase 12), also known as RPN5. is part of the 19S regulatory particle within the ubiquitin-proteasome system (UPS). This system governs intracellular protein degradation, critical for regulating cell cycle progression, apoptosis, and signal transduction. PSMD12 functions as a non-ATPase subunit in the 19S base, assisting in substrate recognition, deubiquitination, and translocation of ubiquitinated proteins into the proteolytic 20S core. Dysregulation of PSMD12 has been implicated in cancer, neurodegenerative disorders, and autoimmune diseases due to its role in maintaining protein homeostasis.
PSMD12 antibodies are widely used in Western blotting, immunohistochemistry, and immunoprecipitation to study protein expression, localization, and interactions. They help elucidate PSMD12's involvement in disease mechanisms, such as tumorigenesis linked to proteasome overactivity or neurodegeneration caused by impaired protein clearance. Recent studies also explore PSMD12 as a potential therapeutic target, with inhibitors under investigation for cancer treatment. When selecting a PSMD12 antibody, researchers prioritize specificity validated via knockout controls, cross-reactivity across species (e.g., human, mouse), and compatibility with intended applications. Commercial antibodies are typically developed in rabbit or mouse hosts, with monoclonal and polyclonal options available for diverse experimental needs.